UBS Maintains Buy on Medline, Raises Price Target to $57

Medline +0.55%

Medline

MDLN

47.93

+0.55%

UBS analyst Kevin Caliendo maintains Medline (NASDAQ: MDLN) with a Buy and raises the price target from $48 to $57.